Aldeyra Therapeutics (ALDX) investor relations material

Executive summary

• Report covers the quarter ended March 31, 2026, for a clinical-stage biotechnology company focused on immune-mediated diseases.

• No products are approved for sale; revenue is primarily from collaboration agreements and financing activities.

• The company is advancing late-stage product candidates, notably reproxalap for dry eye disease, and maintains a single operating segment.

Financial highlights

• Net loss for Q1 2026 was $3.5 million, a significant improvement from $9.9 million in Q1 2025.

• Research and development expenses decreased 67.5% year-over-year to $2.4 million.

• General and administrative expenses fell 62.1% year-over-year to $1.1 million.

• Cash and cash equivalents totaled $65.0 million at March 31, 2026.

• Total stockholders' equity was $42.2 million at quarter end.

Outlook and guidance

• Cash and cash equivalents are expected to fund operations into the second half of 2028, excluding potential licensing and product revenue.

• Additional funding will be needed for full development, regulatory, and commercialization activities.

• The company expects continued operating losses for the foreseeable future.